厄贝沙坦在老年慢性充血性心力衰竭治疗中的作用研究  

Therapeutic Effect of Irbesartan in Elderly Patients with Chronic Congestive Heart Failure

作　　者：许先进 郭万锋 聂红秀 董旭 胡琴兰 钟飞 李伟 

机构地区：[1]湖北省荆门市康复医院心内科,448000 [2]湖北省荆门市康复医院超声影像科

出　　处：《实用心脑肺血管病杂志》2010年第9期1227-1229,共3页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

摘　　要：目的观察厄贝沙坦在老年慢性充血性心力衰竭治疗中的作用。方法老年慢性充血性心力衰竭患者106例,分为治疗组(57例),对照组(49例)。在常规治疗基础上,治疗组加用厄贝沙坦150mg,1次/d,口服。观察治疗前和治疗后4周、12周的NYHA心功能分级、6min步行距离,使用超声心动图测量左心舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)、左室收缩末容积(LVESV)、左室舒张末容积(LVEDV)和左室射血分数(LVEF)。结果 (1)治疗4周、12周后两组病例各心功能指标较治疗前显著改善(P<0.01)。(2)两组比较:治疗4周后治疗组NYHA分级较对照组改善明显(P<0.05);6min步行距离较对照组增加(P<0.05);治疗12周后NYHA分级、6min步行距离、LVEF较对照组增加更为显著(P均<0.01);LVEDD、LVESD与对照组比较显著缩小(P<0.05),LVEDV与对照组比显著下降(P<0.05)。结论厄贝沙坦能改善老年CHF患者的血流动力学状态,改善心功能,抑制神经内分泌活性,抑制心室重构,提高运动耐量,提高生存生活质量,改善预后。Objective To obseve the therapeutic effect of irbesartan in elderly patients with chronic congestive heart failure（CHF）.Methods Elderly patients with chronic congestive heart failure,106 cases were divided into the treatment group（57cases）,the control group（49 cases）.In conventional therapy,the treatment group with irbesartan 150mg,once a day oral.Observed before and after treatment for 4 weeks,12 weeks of NYHA heart function classification,6min walking distance,the use of echocardiography measurement of left ventricular end diastolic diameter（LVEDD）,left ventricular end systolic diameter（LVESD）,left ventricular end systolic volume（LVESV）,left ventricular end diastolic volume（LVEDV） and left ventricular ejection fraction（LVEF）.Results （1）The cardiac function of the two groups with after treatment for 4 weeks,12 weeks were improved significantly compared with before treatment（P〈0.01）.（2）The group of after treatment for 4 weeks the NYHA classification were improved significantly compared with the control group（P〈0.05）.6 minutes walking distance were Increased compared with control group（P〈0.05）.The group of after treatment for12 weeks the NYHA classification,6 minutes walking distance,LVEF were Increased significantly compared with control group（P all0.01）.LVEDD,LVESD were significantly reduced compared with the control group（P〈0.05）,LVEDV were decreased significantly compared with the control group（P〈0.05）.Conclusion Irbesartan can improve the hemodynamic state of elderly CHF patients,improve heart function,inhibition of neuroendocrine activity,inhibition of ventricular remodeling,improve exercise tolerance,improve the life quality of life,improve the prognosis.

关 键 词：老年慢性心力衰竭 厄贝沙坦 心功能 心室重构 

分 类 号：R541.61[医药卫生—心血管疾病]